NTRA Stock Price - Natera, Inc. logo

NTRA Stock Price

Natera, Inc.

$394.75
-$0.90(-0.23%)
57
Overall
40
Value
66
Tech
65
Quality
How is this score calculated?
Market Cap
$56.90B
Volume
1.05M
52W Range
$169.08 - $437.41
Target Price
$382.52

NTRA stock price is $394.75 (-0.23% on the day), giving Natera, Inc. a market cap of $56.90B. Below are the price chart, the MarketXLS Rank, the company profile and the latest news.

NTRA Stock Overview

Price
$394.75
Previous close
$395.65
Open
$394.40
Market cap
$56.90B
P/E ratio
-273.4
52-week range
$169.08 - $437.41
1-year price target
$382.52
Sector
Healthcare
Industry
Diagnostics & Research
Exchange
NGS
MarketXLS Rank
57

About Natera, Inc.

Natera, Inc., a diagnostics company, provides molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera molecular residual disease test for assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based genomic profiling test, that provides insight into genomic alterations and biomarkers; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product. It serves independent laboratories, national and regional reference laboratories, medical centers and physician practices, research laboratories, and pharmaceutical companies through its direct sales force, and a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, LLC and changed its name to Natera, Inc. in January 2012. Natera, Inc. was founded in 2003 and is headquartered in Austin, Texas.

ABCD
1SymbolPriceChangeVol
2NTRA$394.75-0.2%1.05M
3
4
5
6

Get Natera, Inc. Data in Excel

Stream real-time data directly to your spreadsheets

BUY NOW
Stock data provided by MarketXLS.